Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

5-azacitidine and Thalidomide for patients with Myelodysplastic Syndromes to assess safety and efficacy

Next Previous
Search
Trial Profile

5-azacitidine and Thalidomide for patients with Myelodysplastic Syndromes to assess safety and efficacy

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Thalidomide (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions

Most Recent Events

  • 18 Apr 2018 Results assessing genetic biomarkers following treatment with Azacitidine or Thalidomide or Lenalidomide that predict clinical outcomes in MDS in patients enrolled in ALLG MDS3 and MDS4 clinical trials, were presented at the 109th Annual Meeting of the American Association for Cancer Research.
  • 18 May 2017 Status changed from active, no longer recruiting to completed.
  • 25 Jul 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top